VANCOUVER, BC — Kardium Inc. announces the successful first-in-human study of its next generation Globe® Pulsed Field System to treat atrial fibrillation (AF) using pulsed field ablation (PFA) therapy. Working with… Read More
Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients Data showed relative risk reduction in specific study… Read More
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice1,2 Phase III trial also demonstrated a statistically… Read More
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductions BION-1301 is well-tolerated, with… Read More
VANCOUVER, BC — Clairvoyant Therapeutics (“Clairvoyant”), a clinical stage biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the first patient… Read More
